Absci prices $50 million public stock offering at $3 per share

Absci Corporation (NASDAQ: ABSI) priced an underwritten public offering of 16,670,000 shares of common stock at $3.00 per share, the clinical-stage biopharmaceutical company announced. The offering is expected to generate gross proceeds of approximately $50 million before deducting underwriting discounts, commissions and offering expenses.

The company granted underwriters a 30-day option to purchase up to an additional 2,500,500 shares under the same terms. All shares in the offering will be sold by Absci.

Absci stated it intends to use net proceeds to fund advancement of internally developed programs, continued investment in its Integrated Drug Creation platform, and for working capital and general corporate purposes.

Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen serve as joint book-running managers for the offering. The transaction is expected to close on or about July 25, 2025, subject to customary closing conditions.

The shares are being offered pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on August 24, 2022, which became effective on September 2, 2022. A preliminary prospectus supplement and accompanying prospectus was filed with the SEC on July 24, 2025.

Absci develops therapeutics using generative artificial intelligence and operates from Vancouver, Washington, with facilities in New York City and Zug, Switzerland.

You May Also Be Interested In

• Jade Biosciences announces underwritten public offering of common stock
• Fairfax prices $750 million senior notes offering at 6.200% interest
• 3D Systems announces $40 million public stock offering